Last updated on July 2017

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, 52-WEEK EFFICACY AND SAFETY STUDY OF RO5285119 IN ADULTS WITH AUTISM SPECTRUM DISORDERS (ASD) WITH A 2-YEAR OPEN LABEL EXTENSION


Brief description of study

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, 52-WEEK EFFICACY AND SAFETY STUDY OF RO5285119 IN ADULTS WITH AUTISM SPECTRUM DISORDERS (ASD) WITH A 2-YEAR OPEN LABEL EXTENSION

Detailed Study Description

Adult Autism disorder trial with an open label extension

Clinical Study Identifier: TX151026

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )